Beatrice A Golomb1, Abril Verden2, Alexis K Messner3, Hayley J Koslik3, Keith B Hoffman2. 1. Department of Medicine, University of California, San Diego, 9500 Gilman Drive # 0995, La Jolla, CA, 92093-0995, USA. bgolomb@ucsd.edu. 2. Advera Health Analytics, Inc., Santa Rosa, CA, USA. 3. Department of Medicine, University of California, San Diego, 9500 Gilman Drive # 0995, La Jolla, CA, 92093-0995, USA.
Abstract
INTRODUCTION: Apparent elevations in reporting of amyotrophic lateral sclerosis (ALS)-like conditions associated with statin use have been previously described from data obtained via US and European databases. OBJECTIVE: The aim of this study was to examine US FDA Adverse Event Reporting System (FAERS) data to compare reporting odds ratios (RORs) of ALS and ALS-like conditions between statins and other drugs, for each statin agent. METHODS: We assessed for disproportional rates of reported ALS and ALS-related conditions for each statin agent separately by using the ROR formula. FAERS data were analyzed through September 2015. RESULTS: RORs for ALS were elevated for all statins, with elevations possibly stronger for lipophilic statins. RORs ranged from 9.09 (6.57-12.6) and 16.2 (9.56-27.5) for rosuvastatin and pravastatin (hydrophilic) to 17.0 (14.1-20.4), 23.0 (18.3-29.1), and 107 (68.5-167) for atorvastatin, simvastatin, and lovastatin (lipophilic), respectively. For simvastatin, an ROR of 57.1 (39.5-82.7) was separately present for motor neuron disease. CONCLUSION: These findings extend previous evidence showing that significantly elevated ALS reporting extends to individual statin agents, and add to concerns about potential elevated occurrence of ALS-like conditions in association with statin usage.
INTRODUCTION: Apparent elevations in reporting of amyotrophic lateral sclerosis (ALS)-like conditions associated with statin use have been previously described from data obtained via US and European databases. OBJECTIVE: The aim of this study was to examine US FDA Adverse Event Reporting System (FAERS) data to compare reporting odds ratios (RORs) of ALS and ALS-like conditions between statins and other drugs, for each statin agent. METHODS: We assessed for disproportional rates of reported ALS and ALS-related conditions for each statin agent separately by using the ROR formula. FAERS data were analyzed through September 2015. RESULTS: RORs for ALS were elevated for all statins, with elevations possibly stronger for lipophilic statins. RORs ranged from 9.09 (6.57-12.6) and 16.2 (9.56-27.5) for rosuvastatin and pravastatin (hydrophilic) to 17.0 (14.1-20.4), 23.0 (18.3-29.1), and 107 (68.5-167) for atorvastatin, simvastatin, and lovastatin (lipophilic), respectively. For simvastatin, an ROR of 57.1 (39.5-82.7) was separately present for motor neuron disease. CONCLUSION: These findings extend previous evidence showing that significantly elevated ALS reporting extends to individual statin agents, and add to concerns about potential elevated occurrence of ALS-like conditions in association with statin usage.
Authors: Eric Colman; Ana Szarfman; Jo Wyeth; Andrew Mosholder; Devanand Jillapalli; Jonathan Levine; Mark Avigan Journal: Pharmacoepidemiol Drug Saf Date: 2008-11 Impact factor: 2.890
Authors: Colin J Mahoney; Rebekah M Ahmed; William Huynh; Sicong Tu; Jonathan D Rohrer; Richard S Bedlack; Orla Hardiman; Matthew C Kiernan Journal: CNS Drugs Date: 2021-05-15 Impact factor: 5.749
Authors: Marc G Weisskopf; Joseph Levy; Aisha S Dickerson; Sabrina Paganoni; Maya Leventer-Roberts Journal: Am J Epidemiol Date: 2022-06-27 Impact factor: 5.363
Authors: Fardin Nabizadeh; Mohammad Balabandian; Amir Mohammad Sharafi; Ali Ghaderi; Mohammad Reza Rostami; Abdorreza Naser Moghadasi Journal: Acta Neurol Belg Date: 2021-07-28 Impact factor: 2.471
Authors: Wan Yun Ho; Jer-Cherng Chang; Kenneth Lim; Amaury Cazenave-Gassiot; Aivi T Nguyen; Juat Chin Foo; Sneha Muralidharan; Ashley Viera-Ortiz; Sarah J M Ong; Jin Hui Hor; Ira Agrawal; Shawn Hoon; Olubankole Aladesuyi Arogundade; Maria J Rodriguez; Su Min Lim; Seung Hyun Kim; John Ravits; Shi-Yan Ng; Markus R Wenk; Edward B Lee; Greg Tucker-Kellogg; Shuo-Chien Ling Journal: J Cell Biol Date: 2021-08-04 Impact factor: 10.539